The bases remain similar to those in DNA, allowing PNAs to target transcripts. As antisense molecules, PNAs bind to complementary messenger RNA (mRNA), blocking its function and inhibiting the ...

In this phase I trial, Lai and colleagues evaluated the safety and toxicity of EGFR antisense DNA therapy in 20 patients with advanced squamous-cell carcinoma of the head and neck. All patients ...

U of A professor of medical genetics Toshifumi Yokota and the Yokota Lab are making advancements in gene therapy.

Scientists use short oligonucleotides as primers for polymerase chain reaction and next-generation sequencing, in DNA microarrays and fluorescence in situ hybridization, and in antisense therapies. (1 ...

These informational drugs, known as antisense therapies, chemically modify genetic sequences to reach specific targets and block disease-associated mRNA. Agrawal likens these therapies to “genetic ...

Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...

The treatment is antisense oligonucleotide therapy, commonly called ASO. This type of genetic therapy uses short, synthetic DNA sequences to target specific mRNA. N-Lorem, a California-based ...

As surprisingly high proportions of eukaryotic genomes are transcribed, with numerous noncoding and antisense RNAs being ... from evolutionarily unrelated DNA is noise, so analysis of cells ...

Oligonucleotides work as short strands of synthetic DNA or RNA that can reduce ... $40 million from a series A and a group of execs from antisense oligonucleotide-focused Ionis.

AlphaRose is currently advancing its lead antisense oligonucleotide product, Rosiphersen, through IND-enabling studies with a goal of initiating clinical studies in early 2026. AlphaRose is also ...